Jana Arsenijevic

Mrs. Jana Arsenijevic


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
APAleksandra D Petrovic
Aleksandra D Petrovic
ABAna Barjaktarevic
Ana Barjaktarevic
OKOlivera Zoran Kostic
Olivera Zoran Kostic
SMSara Mijailovic
Sara Mijailovic
SJSlobodan Janković
Slobodan Janković
MKMarina Jovica Kostic
Marina Jovica Kostic
Background/Objectives: Adverse effects of antipsychotics represent a significant limiting factor in achieving favorable therapeutic outcomes in the treatment of schizophrenia, and may contribute to a diminished quality of life among affected individuals. The primary objective of this study was to identify and evaluate the adverse effects of antipsychotics in patients diagnosed with schizophrenia who were treated at the social welfare institution, as well as to analyze the impact of these adverse effects on patients’ overall quality of life. Methods: A clinical, observational cross-sectional study was conducted, involving a sample of 278 patients diagnosed with schizophrenia. The patients were assessed in terms of their sociodemographic and clinical characteristics. Adverse effects of antipsychotics were evaluated using The Udvalg for Kliniske Undersøgelser (UKU) Side Effect Rating Scale, while quality of life was assessed in the previous study. Results: The average number of adverse effects per patient with schizophrenia was 3.56 for psychiatric, 1.18 for neurological, 2.62 for autonomic, and 7.12 for other side effects. The average UKU score was 17.22 ± 11.04, with significant differences based on accommodation, antipsychotic type, and dosing regimen. UKU scores were negatively correlated with the EuroQoL 5-Dimension 5-Level (EQ-5D-5L) index, Visual Analog Scale (VAS) score, the Quality-of-Life Enjoyment and Satisfaction Questionnaire—Short Form (Q-LES-Q-SF) score, and the scores of physical and psychological domains of the World Health Organization Quality-of-Life Scale (WHOQOL-BREF). Conclusions: The findings of this study suggest that the presence of antipsychotic-related adverse effects is a significant determinant that can negatively influence the quality of life in patients with schizophrenia. These results underscore the importance of an individualized approach when determining pharmacological treatment strategies in the management of schizophrenia.

30 March 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
JAJana Arsenijevic
Jana Arsenijevic
MSMarijana S. Stanojevic
Marijana S. Stanojevic
DMDragan R. Milovanovic
Dragan R. Milovanovic
MKMarina Jovica Kostic
Marina Jovica Kostic
BJBiljana Popovska Jovičić
Biljana Popovska Jovičić
DJDanijela Jovanovic
Danijela Jovanovic
Background: Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection and remains a leading cause of mortality in intensive care units (ICUs). Although the Sequential Organ Failure Assessment (SOFA) score is widely used for prognostic stratification, organ dysfunction represents a downstream manifestation of sepsis, whereas immune and inflammatory dysregulation may precede overt organ failure. Monocyte distribution width (MDW) is a novel hematological parameter reflecting monocyte activation and is approved for the diagnosis of sepsis; however, its prognostic value and potential role within composite biomarker models in critically ill surgical patients with sepsis remain incompletely defined. Methods: We conducted a prospective, observational, single-center pilot study in two surgical intensive care units between November 2022 and December 2023. Adult patients with sepsis defined according to Sepsis-3 criteria were enrolled. Laboratory and clinical variables—including MDW, neutrophil-to-lymphocyte ratio (NLR), C-reactive protein (CRP), procalcitonin (PCT), and SOFA score—were measured on admission and during the first five days of ICU stay. Patient-level median values across five days were used for analysis. The primary outcome was in-hospital mortality. Prognostic performance was assessed using receiver operating characteristic (ROC) curve analysis and logistic regression. A composite bioscore was constructed by combining dichotomized MDW, NLR, CRP, and PCT values. Results: Sixty patients were included; 24 (40%) died during hospitalization. Non-survivors were older and had significantly higher SOFA scores. MDW, NLR, CRP, and PCT were significantly higher in non-survivors. SOFA demonstrated the strongest discriminative ability for mortality prediction (AUC 0.839, 95% CI 0.730–0.948). Among biomarkers, NLR (AUC 0.741) and PCT (AUC 0.714) showed good discriminative performance, while MDW (AUC 0.690) and CRP (AUC 0.662) showed moderate discrimination; MDW exhibited the highest specificity (80.6%). In multivariable analysis with individual biomarkers, only SOFA remained an independent predictor of mortality. The composite bioscore demonstrated good discriminative ability (AUC 0.805) and, when evaluated alongside SOFA, remained independently associated with fatal outcome (OR 11.92, 95% CI 1.76–80.75); however, given the modest sample size and wide confidence intervals, this finding should be interpreted with caution. Repeated-measures correlation analysis revealed no strong collinearity among biomarkers. Conclusions: A composite bioscore incorporating MDW, NLR, CRP, and PCT provides prognostic information comparable to SOFA and remains independently associated with mortality. This approach may complement organ dysfunction-based assessment and support early risk stratification in sepsis.